That makes a lot of sense. Early adoption could be driven by people who are unhappy with their high disease burden and who will want to act quickly. And these patients could be very, very expensive thus motivating the payers to get these patients treated quickly.
I have been kind of on the fence about whether patients will jump at a quick cure or wait for something that cures them for longer. But I think you are right that the most burdened patients will want to move quickly.
Pfizer may get a multibillion dollar gift from Sangamo. Surely they must realize that they could squander this multibillion dollar gift if they don't act quickly.